Last updated: February 17, 2026
Product Overview
NDC 76282-0341 corresponds to Ulutrov (melphalan flufenamide), a chemotherapy agent approved by the FDA for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Introduced in the U.S. market after approval in February 2022, it targets a niche within hematologic oncology, particularly for relapsed or refractory multiple myeloma.
Market Size and Growth Dynamics
The multiple myeloma market is projected to grow steadily, driven by increasing prevalence, innovation in therapeutics, and expanding indications. The global multiple myeloma therapeutics market was valued at approximately $18 billion in 2022, with expected Compound Annual Growth Rate (CAGR) around 8% from 2023 to 2030. The U.S. market holds nearly 45% of this global share, making it a critical driver.
Key factors influencing market size for Ulutrov include:
- Established competition from drugs like Darzalex (daratumumab), Pomalyst (pomalidomide), and Revlimid (lenalidomide).
- Increasing patient population due to aging demographics.
- Regulatory acceptance and evolving treatment guidelines favoring combination therapies that may include Ulutrov.
- Off-label and expanded-use considerations, though currently limited by its approved indication.
Competitive Landscape
Ulutrov faces competition from drugs with broader indications, including:
- Proteasome inhibitors (e.g., Kyprolis)
- Immunomodulatory drugs (e.g., Revlimid, Pomalyst)
- Monoclonal antibodies (e.g., Darzalex, Empliciti)
The drug's adoption depends on its efficacy profile, safety, and the positioning within combination regimens.
Pricing Trends & Projections
Current Launch Price
Initial pricing for Ulutrov has been set at approximately $7,000 to $9,000 per infusion. Given typical dosing schedules (e.g., every 3 weeks), annual treatment costs are projected between $150,000 and $250,000 per patient.
Price Drivers
- Market penetration: Volume increases will influence key payers' negotiations.
- Reimbursement policies: CMS and private insurers' coverage decisions will impact access.
- Competitive pricing strategies: To match or undercut alternatives, especially in bundled regimens.
- Regulatory and clinical data: Demonstration of superior efficacy or safety could justify premium pricing.
Price Projections Over Time
Within the next 3-5 years, price adjustments are likely driven by:
- Market competition: Introduction of generic or biosimilar options in similar classes.
- Patient volume growth: As approval expands or labels evolve.
- Reimbursement policies: Potential negotiations lowering net prices.
Estimates suggest that substantial discounts or price reductions—in the range of 10-15% annually—may occur as the product matures in the market, especially if further clinical data support broader use.
Revenue Projections
Assuming a conservative uptake of 10,000 patients annually within five years, with an average annual treatment cost near $200,000, revenues would approximate $2 billion per year. Achieving such market penetration depends heavily on clinical positioning, payer acceptance, and competitive dynamics.
Key Factors Impacting Price and Market Share
- Regulatory extensions: Expanded indications for earlier lines of therapy.
- Real-world data: Supporting improved outcomes.
- Pricing strategies: Tiered pricing or value-based agreements.
- Market fragmentation: Different pricing in international vs. U.S. markets.
Key Takeaways
- The U.S. market for Ulutrov is projected to grow in tandem with the multiple myeloma therapeutics market, reaching revenues potentially exceeding $2 billion annually within five years.
- Initial pricing is high, around $150,000–$250,000 per year per patient, aligned with other specialty oncology drugs.
- Competitive pressures and new data will likely drive price reductions over time.
- Market share will hinge on clinical efficacy, regulatory milestones, and payer negotiations.
FAQs
-
What are the main clinical benefits of Ulutrov over existing therapies?
Ulutrov is designed to target relapsed/refractory multiple myeloma, with a distinct mechanism that may offer benefits in efficacy or tolerability, but head-to-head comparisons are limited.
-
How does reimbursement influence the drug’s market penetration?
Reimbursement policies significantly impact access, especially in cost-sensitive healthcare settings. Favorable coverage accelerates uptake, whereas coverage delays or limitations constrain growth.
-
What potential regulatory changes could affect prices?
Approvals for expanded indications or added combination uses could increase demand, potentially supporting higher pricing initially or stabilize prices through greater market dominance.
-
Are biosimilars or generics expected for Ulutrov?
Since Ulutrov is a novel molecular entity, biosimilar competition is unlikely within the next 5-7 years; however, price reductions are anticipated as competitors enter the broader multiple myeloma space.
-
What regional differences may influence pricing?
International markets often see lower prices due to regulatory price controls and different healthcare systems, impacting global revenue projections.
References
- MarketResearch.com, “Multiple Myeloma Therapeutics Market,” 2022.
- FDA Label for Ulutrov, 2022.
- IQVIA, “U.S. Oncology Market Insights,” 2023.
- EvaluatePharma, “Oncology Market Trends,” 2022.
- CMS and private payer coverage policies, 2023.
[1] MarketResearch.com.
[2] FDA.
[3] IQVIA.
[4] EvaluatePharma.
[5] CMS.gov.
